We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Brian Weinshenker MD

Brian G. Weinshenker MD

Professor of Neurology and Consultant, Mayo Clinic, Rochester, Minnesota

Brian G. Weinshenker is Professor of Neurology and Consultant at Mayo Clinic, Rochester, Minnesota. Dr. Weinshenker's major research interests are directed at the understanding of inflammatory demyelinating diseases of the central nervous system including multiple sclerosis including: 1) natural history of multiple sclerosis; 2) defining clinical and radiologic differential diagnosis of inflammatory myelopathy; 3) classification, diagnosis, and treatment of severe inflammatory demyelinating syndromes of the central nervous system including neuromyelitis optica; 4) McArdle’s sign, a recently rediscovered clinical sign that is highly specific for multiple sclerosis.  He was awarded the John J. Dystel award for multiple sclerosis research in 2011 by the American Academy of Neurology and National Multiple Sclerosis Society (USA).


Brian Weinshenker receives royalties from RSR Ltd, Oxford University, Hospices Civil de Lyon, and MVZ Labor PD Dr. Volkmann und Kollegen GbR for a patent of NMO-IgG as a diagnostic test for neuromyelitis optica spectrum disorders, served on adjudication committee for clinical trials in neuromyelitis optica spectrum disorders being conducted by MedImmune/VielaBio and Alexion, and consulted for Chugai/Roche/Genentech and Mitsubishi-Tanabe regarding a clinical trial for neuromyelitis optica spectrum disorders. He has received honoraria for speaking at internal meetings of Genentech, Novartis, and external meetings for Roche.

Recent Contributions to PracticeUpdate:

  1. Defining Benign/Burned-Out MS and Discontinuing DMTs